Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06191848
Other study ID # 75430
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date May 2024
Est. completion date May 2037

Study information

Verified date January 2024
Source University of Melbourne
Contact Angela Cochrane
Phone +61392312364
Email angela.cochrane@svha.org.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a trial of tirzepatide in people with obesity and knee osteoarthritis. The main purpose of this study is to see if tirzepatide can reduce number of these participants who require a knee replacement. Participants will be randomized to take a weekly injection of tirzepatide or a placebo for a total of 72 weeks.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 352
Est. completion date May 2037
Est. primary completion date May 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have a body mass index of = 30 kg/m2. - Report one or more previous unsuccessful attempt to lose body weight via lifestyle modification. - Have been deemed eligible to enter the waiting list for primary knee replacement for the treatment of osteoarthritis in the target joint by an orthopaedic surgeon at one of the participating study sites. - Have moderate-to-severe knee osteoarthritis in the target joint. - Be willing to and capable of learning how to self-inject the study drug and follow study procedures for the duration of the trial. - Provide informed consent to study participation in line with the requirements of the human research ethics committee of the study site. Female participants must either: • Not be of reproductive potential, defined as: - Infertile due to surgical sterilization or congenital anomaly, OR - Post-menopausal defined as: - A woman over the age of 40 years with spontaneous cessation of menses for at least 12 consecutive months (in the absence of medications known to induce amenorrhea), with a follicle-stimulating hormone =40mIU/mL, and a negative pregnancy test prior to study entry, OR - A woman over the age of 55 years with cessation of menses for at least 12 consecutive months (in the absence of medications known to induce amenorrhea), OR - A woman over the age of 55 years that has commenced hormone replacement therapy after a documented diagnosis of menopause. OR • Be of reproductive potential, and: - Test negative for pregnancy on the initial screening visit via a serum pregnancy test, AND - Use at least two effective forms of contraception, if sexually active, for the duration of the trial and until one month after the last injection of the study drug AND - Not be breastfeeding. Exclusion Criteria: - Have been deemed eligible to enter the waiting list for knee replacement in the contralateral knee by an orthopaedic surgeon at one of the participating study sites. - Have used any prescription medications intended to promote weight loss (e.g., tirzepatide, liraglutide, semaglutide) in the three months prior to screening. - Have previously undergone any surgical or endoscopic procedure intended to promote weight loss. - Have been diagnosed with type 1 diabetes mellitus (T1DM) or T2DM - Have laboratory evidence indicative of diabetes mellitus during screening. - Have personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) - Have an active malignancy (excluding basal or squamous cell skin cancer). - Have had a transplanted organ or awaiting an organ transplant - Have evidence of a significant, active autoimmune abnormality (e.g., lupus or rheumatoid arthritis) - Have any other medical conditions, abnormal laboratory tests or concomitant medications that make them unsuitable for participation: - Have a clinically significant gastric emptying abnormality. - Have had a history of acute or chronic pancreatitis. - Have obesity induced by other endocrinologic disorders - Have an unstable psychiatric disorder - Have uncontrolled hypertension (systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg) - Have had within the past 6 months prior to randomisation any of the following: acute myocardial infarction, cerebrovascular accident, unstable angina, or hospitalisation due to congestive cardiac failure (are also exclusion criteria for elective knee replacement) - Have renal impairment as measured by a serum Creatinine of =0.3 mg/dL (=26.5 µmol/L) at screening visit - Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 mIU/L at screening visit - Have acute or chronic hepatitis or abnormal liver function tests as measured by either alanine aminotransferase or alkaline phosphatase >200 IU. - Have a calcitonin level at Visit 1 of: =20 ng/L with eGFR =60 mL/min/1.73 m2, or =35 ng/L with eGFR <60 mL/min/1.73 m2. - Have any other known contraindication to any glucagon-like peptide-1 receptor agonists. - Are study site personnel, or immediate family of a member of the study site. - Have been enrolled in any other study of an investigational product within the past ninety days or are currently enrolled in such a study

Study Design


Intervention

Drug:
Tirzepatide
Participants will receive tirzepatide subcutaneously
Placebo
Participants will receive placebo subcutaneously

Locations

Country Name City State
Australia St Vincent's Hospital Melbourne Fitzroy Victoria

Sponsors (2)

Lead Sponsor Collaborator
University of Melbourne Eli Lilly and Company

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients who undergo knee replacement in the target joint Percentage of patients who undergo knee replacement in the target joint within 72 weeks of randomization
Secondary Osteoarthritis Pain Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score. The WOMAC Pain subscale has 5-items, with a possible score range of 0-20, with higher scores indicating worse pain. Baseline, Week 72
Secondary Osteoarthritis Function Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function Subscale Score. The WOMAC Function subscale has 17-items, with a possible range of 0-68, with higher scores indicating worse functional impairment. Baseline, Week 72
Secondary Osteoarthritis Stiffness Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score. The WOMAC Stiffness subscale has 2-items, with a possible range of 0-8, with higher score indicating worse stiffness. Baseline, Week 72
Secondary Percentage change in bodyweight Mean percentage change in body weight at 72 weeks after randomization Baseline, Week 72
Secondary =5% body weight reduction Percentage of participants with =5% body weight reduction at 72 weeks after randomization Baseline, Week 72
Secondary =10% body weight reduction Percentage of participants with =10% body weight reduction at 72 weeks after randomization Baseline, Week 72
Secondary =20% body weight reduction Percentage of participants with =20% body weight reduction at 72 weeks after randomization Baseline, Week 72
Secondary Physical Health Mean change in the 12-item Short Form (SF-12) Physical Component Summary at 72 weeks after randomization. The SF-12 Physical Component Summary has a score range of 24.00-56.58, with a lower score indicating poorer physical health. Baseline, Week 72
Secondary Mental Health Mean change in the 12-item Short Form Survey (SF-12) Mental Component Summary at 72 weeks after randomization. The SF-12 Mental Component Summary has a score range of 19.06-60.76, with a lower score indicating poorer mental health. Baseline, Week 72
Secondary Physical Activity Mean change in Physical Activity Scale for the Elderly (PASE) score at 72 weeks after randomization. The PASE has 12-items with a total score range from 0-400 or more, with higher scores indicating greater physical activity. Baseline, Week 72
Secondary Non-opioid prescription pain medication use Proportion of participants reporting use of non-opioid prescription analgesics between 68-72 weeks after randomization Baseline, between 68-72 weeks
Secondary Opioid prescription pain medication use Proportion of participants reporting use of prescription opioid analgesics between 68-72 weeks after randomization Baseline, between 68-72 weeks
Secondary Mean change in use of prescription opioid pain medication Mean change in prescription opioids dose at 72 weeks after randomization Baseline, between 68-72 weeks
Secondary Participant willingness to undergo knee replacement surgery Proportion of patients who undergo knee replacement in the target joint within 72 weeks of randomization or re-enter the waiting list within 72 weeks of randomization. within the 72 weeks since randomization
Secondary Long-term (5-year) progression to knee replacement Percentage of patients who undergo knee replacement in the target joint within 5-years within 260 weeks of randomization
Secondary Long-term (10-year) progression to knee replacement Percentage of patients who undergo knee replacement in the target joint within 10-years within 520 weeks of randomization
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2